Belite Bio, Inc
BLTE
$65.36
$0.360.55%
| 12/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 6.82M | 6.23M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 31.67M | 31.43M | -- | -- |
| Operating Income | -- | -31.67M | -31.43M | -- | -- |
| Income Before Tax | -- | -31.62M | -31.42M | -- | -- |
| Income Tax Expenses | -- | 9.00K | 10.00K | -- | -- |
| Earnings from Continuing Operations | -- | -31.63 | -31.43 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -31.63M | -31.43M | -- | -- |
| EBIT | -- | -31.67M | -31.43M | -- | -- |
| EBITDA | -- | -31.59M | -31.37M | -- | -- |
| EPS Basic | -- | -1.24 | -1.27 | -- | -- |
| Normalized Basic EPS | -- | -0.15 | -0.17 | -- | -- |
| EPS Diluted | -- | -1.24 | -1.27 | -- | -- |
| Normalized Diluted EPS | -- | -0.15 | -0.17 | -- | -- |
| Average Basic Shares Outstanding | -- | 102.37M | 98.99M | -- | -- |
| Average Diluted Shares Outstanding | -- | 102.37M | 98.99M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
